Serina Therapeutics to Present at Roth Conference, Highlighting POZ Platform
Event summary
- Serina Therapeutics CEO Steve Ledger will present at the 38th Annual Roth Conference on March 24, 2026.
- The fireside chat will be webcast live and archived for 90 days.
- Serina is developing its proprietary POZ Platform™ for drug optimization.
- Serina has a non-exclusive license agreement with Pfizer for use of its POZ polymer technology in lipid nanoparticle drug delivery.
The big picture
Serina Therapeutics’ POZ Platform represents a novel approach to drug delivery, aiming to improve the efficacy and safety of existing therapeutics. The company’s reliance on out-licensing and partnerships, as evidenced by the Pfizer agreement, suggests a strategy of leveraging its technology rather than solely relying on internal drug development. The Roth Conference presentation provides a key opportunity to assess the progress and potential of this strategy, particularly given the challenges inherent in developing treatments for neurological diseases.
What we're watching
- Clinical Progress
- The presentation will likely detail progress on SER-252, and investor sentiment will hinge on any updates regarding clinical trial enrollment and data readouts, given the narrow therapeutic window of apomorphine.
- Partnership Impact
- The success of the Pfizer partnership will be a key indicator of the broader applicability of the POZ platform, and further out-licensing deals could significantly impact Serina’s revenue potential.
- Financial Stability
- Given the cautionary language regarding Serina’s ability to continue as a going concern, investors should monitor the company’s cash runway and ability to secure additional funding to support its clinical programs.
Related topics